A phase III study presented at the 14th annual meeting of the Migraine Trust International Research Symposium (MTIRS) in September in London showed that topiramate (Topamax) significantly reduced migraine frequency at doses as low as 100 mg/d. The onset of efficacy was observed as early as the first month of treatment. Topiramate is already approved in the United States and worldwide as an

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

From the MTIRS: Anticonvulsant reduces migraine headache frequency

Newsletter